Skip to main content

Dianthus Therapeutics

Dianthus Therapeutics Inc is an American clinical-stage biotechnology company developing targeted complement therapies for severe autoimmune diseases. The company engineers monoclonal antibodies that selectively inhibit active complement pathway proteins, including lead candidate DNTH103. Main revenue drivers currently comprise investment capital, milestone grants, and development licensing collaborations as clinical pipelines advance. Dianthus Therapeutics targets clinical research centers, rheumatology specialists, and patients suffering from rare autoimmune neuromuscular and hematologic disorders. The company holds a specialized market position in next-generation complement biology drug design. Headquartered in Waltham, Massachusetts, Dianthus Therapeutics Inc is listed on the Nasdaq Stock Market.

7 of the funds FundTelligence covers report a position in Dianthus Therapeutics.

Legal name
Dianthus Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
7
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding Dianthus Therapeutics

Loading...